EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma
- 1Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University
- 2Department of Epidemiology and Health Statistics, School of Public Health, and Hebei Province Key Laboratory of Environment and Human Health, Hebei Medical University
Abstract
Background and purpose: The survival benefit of elective nodal irradiation (ENI) over involved-field irradiation (IFI) in ESCC remains unclear, suggesting uncharacterized systemic costs. Radiation-induced lymphopenia (RIL) is increasingly recognized as an adverse prognostic factor that may undermine antitumor immunity. We investigated whether ENI increases EDRIC, a validated dosimetric biomarker of RIL, and whether EDRIC mediates ENI’s survival disadvantage via immune injury.
Methods: This retrospective cohort study analyzed 279 ESCC patients treated with definitive concurrent chemoradiotherapy (2011- 2015). EDRIC was computed using a validated model incorporating mean lung, heart, and body doses and fraction number. Inverse probability weighting balanced 14 baseline covariates. Causal mediation analysis within the counterfactual framework quantified the proportion of the total effect of radiotherapy field strategy on OS mediated by EDRIC.
Results: ENI significantly elevated EDRIC compared with IFI (8.17 vs. 7.42 Gy; P = 0.01). High EDRIC (>7.8 Gy) independently predicted worse OS (HR = 1.746; P<0.001), PFS, and LRFFS. The IFI- low EDRIC subgroup achieved the best 10- year OS (28.3%), significantly superior to both IFI- high EDRIC (12.0%; P = 0.004) and ENI- H group (13.5%; P = 0.024). ENI increased mortality risk by 52% (total effect Rte=1.52; P = 0.016). Causal mediation analysis revealed that EDRIC mediated 33% of this effect (indirect effect Rtnie=1.13; 95% CI: 1.02-1.29; P = 0.015).
Conclusion: Elevated EDRIC was statistically associated with one-third of ENI’s excess mortality risk. Applying the exploratory 7.8 Gy median cutoff, low-EDRIC IFI was associated with superior long-term survival, suggesting a potential immunoprotective strategy that warrants further validation. These findings support optimizing radiotherapy field design to preserve host immunity in future combination regimens.
Related
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Vitamin D receptor is associated with farnesyl diphosphate synthase protein stability and malignant phenotypes in esophageal squamous cell carcinoma cells
- Cap-assisted photodynamic therapy for esophageal cancer: precise irradiation field control for tumor-confined treatment.
- Genomic alterations associated with response to neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.
- Tumor-associated calcium signal transducer 2 expression as a promising therapeutic target in esophageal squamous cell carcinoma: a combined the Cancer Genome Atlas and an institutional cohort
BibTeX
@article{ren2026edricassociated,
title = {{EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma}},
author = {Xuejiao Ren and Li Li and Xiuyuan Fan and Shuchai Zhu and Haitao Yang and Wenzhao Deng and Lihong Liu and Chun Han and Lan Wang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1911745},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1911745/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma
AU - Xuejiao Ren
AU - Li Li
AU - Xiuyuan Fan
AU - Shuchai Zhu
AU - Haitao Yang
AU - Wenzhao Deng
AU - Lihong Liu
AU - Chun Han
AU - Lan Wang
PY - 2026
DA - 2026/10/26
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1911745
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1911745/full
AB - Background and purpose: The survival benefit of elective nodal irradiation (ENI) over involved-field irradiation (IFI) in ESCC remains unclear, suggesting uncharacterized systemic costs. Radiation-induced lymphopenia (RIL) is increasingly recognized as an adverse prognostic factor that may undermine antitumor immunity. We investigated whether ENI increases EDRIC, a validated dosimetric biomarker of RIL, and whether EDRIC mediates ENI’s survival disadvantage via immune injury. Methods: This retrospective cohort study analyzed 279 ESCC patients treated with definitive concurrent chemoradiotherapy (2011- 2015). EDRIC was computed using a validated model incorporating mean lung, heart, and body doses and fraction number. Inverse probability weighting balanced 14 baseline covariates. Causal mediation analysis within the counterfactual framework quantified the proportion of the total effect of radiotherapy field strategy on OS mediated by EDRIC. Results: ENI significantly elevated EDRIC compared with IFI (8.17 vs. 7.42 Gy; P = 0.01). High EDRIC (>7.8 Gy) independently predicted worse OS (HR = 1.746; P<0.001), PFS, and LRFFS. The IFI- low EDRIC subgroup achieved the best 10- year OS (28.3%), significantly superior to both IFI- high EDRIC (12.0%; P = 0.004) and ENI- H group (13.5%; P = 0.024). ENI increased mortality risk by 52% (total effect Rte=1.52; P = 0.016). Causal mediation analysis revealed that EDRIC mediated 33% of this effect (indirect effect Rtnie=1.13; 95% CI: 1.02-1.29; P = 0.015). Conclusion: Elevated EDRIC was statistically associated with one-third of ENI’s excess mortality risk. Applying the exploratory 7.8 Gy median cutoff, low-EDRIC IFI was associated with superior long-term survival, suggesting a potential immunoprotective strategy that warrants further validation. These findings support optimizing radiotherapy field design to preserve host immunity in future combination regimens.
SN - 1664-3224
ER -